The Diabesity Institute

THE INSTITUTE FINALIZED CURRICULUM MATERIAL AND RELEASED AN ELECTRONIC COPY TO GEORGETOWN UNIVERSITY MEDICAL SCHOOL TO BE INCLUDED IN THEIR SYSTEMS MEDICINE CURRICULUM. DR. COOPER PROVIDED TWO LECTURES TO THE GEORGETOWN UNIVERSITY SYSTEMS MEDICINE CLASS. THE AUDIENCE CONSISTED OF PRE-MED, PUBLIC HEALTH AND HEALTH POLICY UNDERGRADUATE AND GRADUATE STUDENTS. ONE LECTURE PERTAINED TO A SYSTEMS APPROACH IN EVALUATING AND TREATING METABOLIC DISEASE, AND THE OTHER FOCUSED ON REFRAMING THE ISSUE OF DIABESITY, FROM SECTION 1 OF OUR CURRICULUM PROJECT, DEVELOPED IN PRIOR YEARS. WE HOPE TO PRESENT THE ENTIRE SECTION 1 (LEVEL 1) MATERIAL TO HEALTHCARE PROFESSIONALS IN ACADEMIC AND CLINICAL SETTINGS IN 2023. THE INSTITUTE CONTINUED DEVELOPING A SOFTWARE INTERFACE TOOL IN COLLABORATION WITH COOPER CENTER FOR METABOLISM. IT REBUILT THE SOFTWARE TOOLS IN MORE OF AN OPEN-SOURCE, ECONOMICAL VERSION VS. THE PRIOR PROPRIETARY, EXPENSIVE, AND LIMITED SOFTWARE FORMAT. BUILDING ON OUR PROGRESS IN 2021, IN 2022, WE HAVE SEMI-AUTOMATED THE DATA ACQUISITION TO THE DATABASE FROM CLINICAL PLATFORMS, MADE POSSIBLE VIA DATA TRANSFERS FROM ELECTRONIC MEDICAL RECORDS SYSTEMS. WE HAVE ALSO EXPANDED OUR DATA VISUALIZATION BY AGGREGATING DATA ACROSS VARIOUS DEMOGRAPHIC TIERS. DR. COOPER HAS PRESENTED THIS DATA NUMEROUS TIMES IN 2022 TO CLINICIANS, SMALL ACADEMIC GROUPS AND RESEARCH SCIENTISTS IN THE DIABESITY FIELD.DI HOPES TO SHARE THESE ROBUST CLINICAL DATASETS WITH ADDITIONAL CLINICAL PRACTICES AND ACADEMIC CENTERS FOR CLINICAL TRAINING AND POTENTIAL PUBLICATION RELATED TO CLINICAL OUTCOMES IN DIABESITY PATIENTS. THE SOFTWARE CONTINUES TO PROVIDE DATA VALUABLE IN TRACKING CLINICAL TRENDS IN A GROWING SUBSET OF OVER ONE THOUSAND ADULT PATIENTS AND TWO HUNDRED PEDIATRIC PATIENTS WHOSE TARGETED TREATMENT INCORPORATED THE SOFTWARE INTERFACE TOOL. THE DATA ANALYZED INCLUDE THE PERCENT CHANGE IN BODY WEIGHT AND BMI PERCENTILE IN ADULTS AND CHILDREN WITH OBESITY AND THE PERCENT CHANGE IN HBA1C, LDL CHOLESTEROL PARTICLES, FATTY LIVER MARKERS, AND HYPERTENSION MARKERS IN ADULTS AND CHILDREN WITH PREDIABETES.IN 2023, WE HOPE TO EXPAND OUR CLINICAL TRAINING AND DATA ANALYSIS TO ENABLE MORE CLINICIANS TO PARTICIPATE IN INCREASING ACCESS TO CARE FOR DIABETIC PATIENTS.